Clinical development will be initiated in the first half of 2008.

Neogenix Oncology and Goodwin Biotechnology entered into an agreement for process development and manufacturing of Neogenix’ first therapeutic product. NPC-1C is a mAb intended for the treatment of advanced pancreatic cancer.

Neogenix expects to begin Phase I and Phase II trials of the product during the first half of 2008.

Previous articleToyama Chemical Licenses RA Drug to Roche for Potentially More Than $370M
Next articleIntradigm Selects Agilent as Manufacturing Partner for RNAi Oncology Therapeutic